Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2023

May 12, 2023

SELL
$21.91 - $32.67 $381,891 - $569,438
-17,430 Reduced 9.0%
176,131 $4.06 Million
Q4 2022

Feb 08, 2023

SELL
$26.28 - $33.92 $165,406 - $213,492
-6,294 Reduced 3.15%
193,561 $5.38 Million
Q3 2022

Nov 09, 2022

SELL
$25.97 - $38.53 $60,302 - $89,466
-2,322 Reduced 1.15%
199,855 $6.13 Million
Q4 2021

Feb 10, 2022

BUY
$42.59 - $55.02 $34,199 - $44,181
803 Added 0.4%
202,177 $9.02 Million
Q3 2021

Nov 10, 2021

BUY
$48.48 - $78.23 $131,526 - $212,237
2,713 Added 1.37%
201,374 $10.2 Million
Q2 2021

Aug 13, 2021

BUY
$50.3 - $78.44 $1.78 Million - $2.77 Million
35,329 Added 21.63%
198,661 $15.6 Million
Q1 2021

May 14, 2021

BUY
$53.8 - $81.53 $507,549 - $769,154
9,434 Added 6.13%
163,332 $9.33 Million
Q4 2020

Feb 02, 2021

BUY
$36.89 - $93.56 $410,438 - $1.04 Million
11,126 Added 7.79%
153,898 $12.9 Million
Q3 2020

Nov 05, 2020

BUY
$23.13 - $38.84 $83,268 - $139,824
3,600 Added 2.59%
142,772 $5.12 Million
Q2 2020

Aug 12, 2020

BUY
$16.01 - $28.82 $488,288 - $878,981
30,499 Added 28.06%
139,172 $3.37 Million
Q1 2020

May 12, 2020

BUY
$14.2 - $27.98 $1,420 - $2,798
100 Added 0.09%
108,673 $1.9 Million
Q4 2019

Jan 27, 2020

BUY
$14.4 - $19.99 $286,560 - $397,800
19,900 Added 22.44%
108,573 $1.89 Million
Q3 2019

Oct 31, 2019

BUY
$15.32 - $21.92 $1.12 Million - $1.61 Million
73,291 Added 476.47%
88,673 $1.36 Million
Q2 2019

Aug 15, 2019

BUY
$18.5 - $28.14 $107,300 - $163,212
5,800 Added 60.53%
15,382 $319,000
Q1 2019

May 03, 2019

BUY
$17.99 - $24.65 $172,380 - $236,196
9,582 New
9,582 $222,000

Others Institutions Holding DNLI

About Denali Therapeutics Inc.


  • Ticker DNLI
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 134,174,000
  • Market Cap $3.12B
  • Description
  • Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. It offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidate, including BIIB122/DNL151, a small molecule inhibitor, which is in phase I and phase Ib clinical trials for the treatm...
More about DNLI
Track This Portfolio

Track California Public Employees Retirement System Portfolio

Follow California Public Employees Retirement System and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of California Public Employees Retirement System, based on Form 13F filings with the SEC.

News

Stay updated on California Public Employees Retirement System with notifications on news.